Amadeus Capital Partners is an investor backing trailblazers solving hard problems across intelligence, human, and planet technology areas from seed to growth stages.
The financing will support international expansion and development of the Deltaflow operating system.
"For a quantum ecosystem to thrive, we urgently need an operating system. An operating system makes quantum computers useful – it allows programs and applications to run on many different machines. Riverlane aims to make our operating system Deltaflow a global standard."
The seed round was led by Amadeus Capital Partners with participation from Partech, Air Street Capital, and Miele Venture.
"The story of the last 5 years for AI-first companies has been one of rapidly evolving tooling and infrastructure best practices. The very best AI-first companies are now moving from their home-grown data annotation, versioning and model lifecycle management tools to V7’s SaaS platform because it abstracts this complexity and exposes industry best practices. Companies can now iterate faster and have confidence in the robustness of their production models by building on V7."
The round was co-led by AlbionVC and Cambridge Innovation Capital to support commercial expansion and research.
"There’s never been a greater need to effectively deploy ML models in enterprise, and this fresh capital injection will ensure our customers have the tools they need to achieve their goals."
Amadeus Capital Partners led the seed round with participation from Speedinvest and existing backers.
"Video files are typically large in size and present unique challenges of scale and security for access, processing, review and supply compared to other data. Without specialist automation data security is impossible to manage at any scale. Our products are currently being used in the preparation of video evidence, the anonymisation of visual data for analytics and for compliance with GDPR and other data protection legislation."
The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.
"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"
